One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era?
doi : 10.1200/JCO-24-01303
2024, Volume 42 (28)
Effect of an Invitation or the Effect of Participation: What Should Randomized Controlled Trials of Cancer Screening Examine?
doi : 10.1200/JCO.23.01673
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
doi : 10.1200/JCO.23.01960
Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
doi : 10.1200/JCO.24.00184
Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies
doi : 10.1200/JCO.24.00582
Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer
doi : 10.1200/JCO.24.00582
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)
doi : 10.1200/JCO.23.02261
15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
doi : 10.1200/JCO.24.00447
Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study
doi : 10.1200/JCO.24.00038
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer
doi : 10.1200/JCO.23.01488
Mechanisms by Which the Intratumoral Microbiome May Potentiate Immunotherapy Response
doi : 10.1200/JCO.24.00908
Reduction in Esophageal Cancer Incidence and Mortality by Screening Endoscopy
doi : 10.1200/JCO.24.00557
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1 -Mutated Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer?
doi : 10.1200/JCO.24.00992
